“Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE)”, Reumatismo, vol. 71, no. 1, pp. 24–30, Apr. 2019, doi: 10.4081/reumatismo.2019.1154.